BPC-157Cellular PeptideSafety Rating 7/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Price Comparison
Compare vendors · per 10mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| Puratek PeptidesBest $/mgCOA ✓ · 3P | $26.95 | $2.70 | May 19, 2026 | Buy → |
| Red River PeptidesCOA ✓ · 3PAvailable on backorder | $29.75 | $2.98 | May 19, 2026 | Buy → |
| Optimum FormulaCOA ✓ · 3P | $34.19 | $3.42 | May 14, 2026 | Buy → |
| Ascension PeptidesCOA ✓ · 3P | $35.00 | $3.50 | Apr 16, 2026 | Buy → |
| Evolve PeptidesCOA ✓ · 3POut of stock | $55.25 | $3.68 | Apr 22, 2026 | Buy → |
Overview
About BPC-157
Mechanism of action
Upregulates growth hormone receptors, promotes angiogenesis, activates the FAK-paxillin pathway, modulates nitric oxide synthesis, and stimulates tendon/ligament fibroblast growth factor expression.
Safety profile
Generally well-tolerated. Possible: nausea, dizziness, hot/cold flashes, temporary fatigue. No significant toxicity reported in animal studies. · Extensive preclinical safety; 3 small human studies with zero adverse events; naturally derived gastric peptide
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops BPC-157 below your target.
Safety & Interactions
Contraindications & Drug Interactions
Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.
Active malignancy — angiogenic/growth-promoting effects in preclinical models warrant avoidance during cancer treatment.
Pregnancy and lactation — no human safety data; avoid.
May theoretically additively enhance tissue repair when combined with TB-500, though no clinical data confirms the interaction.
Related pages
More on BPC-157
Stack & Compare
Frequently Researched Together
Learn More
BPC-157 Guide
Learn how BPC-157 works, what the research says, and how to compare prices across vendors.
Read full guide · 9 min read →Research
Studies & key findings
- First published human safety data (2025 pilot study) confirmed intravenous BPC-157 was well-tolerated in humans, supporting translation from extensive preclinical work.
- Accelerates tendon-to-bone healing, ligament repair, and GI ulcer healing via activation of the Src-Cav-1-eNOS signaling axis and VEGFR2-mediated angiogenesis.